Early use of PCSK9i in Chinese heart attack patients
Treatments studied
Part of Heart & circulation clinical trials.
This study looks back at medical records of Chinese patients who had a heart attack or unstable angina. It compares outcomes for those who started a newer cholesterol-lowering shot (Alirocumab, brand name Praluent) plus a statin while in the hospital, versus those who only took a statin pill. The goal is to see if starting the shot early helps improve heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were hospitalized with a heart attack or unstable angina (Acute Coronary Syndrome).
- You are 18 years old or older.
- You started Alirocumab (Praluent) along with a statin (with or without ezetimibe) during your hospital stay or at discharge, OR you were treated with a statin alone (with or without ezetimibe) as a comparison.
- You have at least one follow-up visit recorded after leaving the hospital.
- You have never taken Evolocumab (Repatha) or Inclisiran (Leqvio) for cholesterol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if starting inclisiran soon after a heart attack helps lower cholesterol further in patients already on statins. The goal is to see if early treatment can reduce future heart risks.
This study looks at how to best coordinate care between your regular doctor and heart specialists if you have chronic heart disease. It tests whether a special program helps you stay on the right medications to lower cholesterol.
This study tests whether starting strong cholesterol-lowering treatment early in the hospital can improve outcomes for people with acute coronary syndrome (a serious heart condition like a heart attack or unstable angina). It may help if you have high LDL cholesterol.
This study tests whether starting a cholesterol-lowering drug called a PCSK9 inhibitor soon after a heart attack can help prevent future blockages. If you had a heart attack, received a stent, and have other arteries with minor blockages, this trial may be for you.
This study tests a new medication called selatogrel in people with chronic coronary syndrome (long-term heart disease caused by narrowed heart arteries). Researchers want to see how the body processes this drug and whether it helps prevent future heart problems.
This study tests whether starting evolocumab (a cholesterol-lowering injection) soon after a heart attack helps prevent future heart problems. You'll receive the study drug or placebo for 52 weeks while your heart is monitored with imaging scans.
Hear when a new Acute Coronary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.